8-K: Sensei Biotherapeutics Pro Forma Financials Released

Sensei Biotherapeutics files pro forma financial data ahead of the June 10, 2026, shareholder vote on Series B Preferred Stock conversion.

Summary

• The company is preparing for the conversion of Series B Non-Voting Convertible Preferred Stock into common stock.
• The conversion is subject to shareholder approval at the Annual Meeting scheduled for June 10, 2026.
• Pro forma financial information reflects the impact of converting 24,434.92 shares of Series B Preferred Stock into 24,434,920 shares of common stock.
• The conversion would significantly increase the weighted-average shares outstanding from 1,295,052 to 25,729,972 for the quarter ended March 31, 2026.
• The pro forma adjustment reclassifies $321.86 million from redeemable convertible preferred stock to stockholders' equity.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing required to facilitate a previously announced capital structure change and acquisition integration.

Positives

• The conversion of preferred stock into common stock simplifies the capital structure.
• The company successfully raised $200 million in gross proceeds via a PIPE financing in February 2026.
• The pro forma balance sheet shows a strengthened stockholders' equity position of $184.57 million post-conversion.

Negatives

• The conversion results in significant dilution for existing common stockholders.
• The company reported a substantial net loss of $170.24 million for the first quarter of 2026.
• The pro forma net loss per share is adjusted to $(6.62) based on the increased share count.

Risks

• The conversion is contingent upon shareholder approval at the June 10, 2026, meeting.
• Beneficial ownership limitations may prevent the conversion of certain shares, making the final share count uncertain.
• The pro forma financial information is illustrative and may not reflect the actual financial condition post-conversion.
• The company faces high operating expenses, including $132.96 million in acquired in-process research and development costs.

Future Outlook

The company expects the conversion of Series B Preferred Stock to occur three business days following the affirmative shareholder vote at the June 10, 2026, Annual Meeting.

Management Comments

• Management notes that the pro forma information is for illustrative purposes and may not reflect the final financial condition post-conversion.

Industry Context

StockSavvy.ai notes that Sensei Biotherapeutics is utilizing significant equity financing and preferred stock structures to fund its R&D and acquisition strategy, a common trend in the cash-intensive clinical-stage biotechnology sector.

Comparison to Industry Standards

• The use of PIPE (Private Investment in Public Equity) financing is a standard mechanism for biotech firms to secure capital for acquisitions and clinical trials.
• The high ratio of R&D expenses relative to revenue is typical for pre-commercial stage biotechnology companies.

Corporate Governance

Stakeholder Impact

• Existing shareholders will face significant dilution upon the conversion of the Series B Preferred Stock.
• The conversion will result in a change of control of the company.

Next Steps

• Hold the Annual Meeting of stockholders on June 10, 2026.
• Obtain shareholder approval for the conversion of Series B Preferred Stock.
• Execute the conversion of Series B Preferred Stock three business days after the vote.

Key Dates

Recommendation

The significant dilution associated with the pending conversion of preferred stock and the company's high cash burn rate warrant a cautious hold position until the integration of the recent acquisition shows clear clinical or operational progress.

Keywords

Sensei Biotherapeutics, SNSE, Biotech, Preferred Stock Conversion, Pro Forma Financials, PIPE Financing, Merger